Chimeric antigen receptor (CAR) T-cell therapy is a type of cancer immunotherapy where patients' T-cells are collected and genetically modified to produce chimeric antigen receptors that recognize specific targets on cancer ...
Dec 17, 2024
0
0
A study by the Karl Landsteiner University of Health Sciences (KL Krems) highlights crucial findings regarding the infrequent check-ups among women with breast implants. An analysis of more than 1,000 cases revealed that ...
Dec 17, 2024
0
1
A simple change to the chemotherapy regimen for people with Hodgkin lymphoma could reduce the long-term health impacts that can result from treatment, according to researchers in Cambridge. The findings could lead to the ...
Dec 12, 2024
0
31
Late-breaking research reveals there is no benefit from high-dose chemotherapy followed by autologous stem cell transplant (ASCT) for patients with mantle cell lymphoma (MCL) in remission following their initial treatment. ...
Dec 10, 2024
0
0
About a third of patients with diffuse large B cell lymphoma (DLBCL), a fast-growing form of lymphoma, will see their disease advance or recur following treatment. Seeking a new treatment strategy that might boost the effectiveness ...
Dec 10, 2024
0
1
Two clinical trials testing the antibody loncastuximab tesirine (Zynlonta) showed encouraging results in patients with high-risk forms of two blood cancers—follicular lymphoma and marginal zone lymphoma.
Dec 9, 2024
0
47
Autologous hematopoietic cell transplant (auto-HCT) is not beneficial for patients with mantle cell lymphoma (MCL) in first complete remission (CR) with undetectable minimal residual disease (uMRD), according to a study to ...
Dec 6, 2024
0
0
An emerging class of anticancer drugs called EZH2 inhibitors may greatly enhance the potency of some cancer immunotherapies, according to a preclinical study led by Weill Cornell Medicine lymphoma researchers.
Dec 5, 2024
0
7
Continuous enrollment in Medicaid was associated with a lower rate of a late-stage lymphoma diagnosis in children and adolescents/young adults (AYAs). However, fewer than half of Medicaid-insured patients in these age ranges ...
Nov 12, 2024
0
0
A treatment that rallies the immune system to destroy cancer raised the survival rate for advanced Hodgkin lymphoma patients to a remarkable 92%, suggesting a new standard therapy for the disease. The New England Journal ...
Oct 16, 2024
1
75
